Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
synthetic estrogen
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
patch
tablet ring |
| gptkbp:brand |
gptkb:Ortho_Tri-Cyclen
Yasmin NuvaRing |
| gptkbp:chemicalFormula |
estrogen
C20H24O2 |
| gptkbp:clinicalTrials |
Phase 3
|
| gptkbp:composedOf |
chemical synthesis
|
| gptkbp:contraindication |
liver disease
breast cancer uncontrolled hypertension history of thromboembolic disorders |
| gptkbp:dissolved |
insoluble in water
soluble in ethanol soluble in chloroform |
| gptkbp:gestationPeriod |
X
|
| gptkbp:hasFacilities |
296.4 g/mol
|
| https://www.w3.org/2000/01/rdf-schema#label |
ethinyl estradiol
|
| gptkbp:impact |
thickens endometrial lining
|
| gptkbp:interactsWith |
smoking
certain antibiotics anticonvulsants |
| gptkbp:isATypeOf |
57-63-6
|
| gptkbp:locatedIn |
1950s
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:numberOfStudents |
13-27 hours
|
| gptkbp:nutritionalValue |
liver
|
| gptkbp:occursAnnually |
regulates menstrual cycle
|
| gptkbp:phonology |
inhibits ovulation
|
| gptkbp:relatedPatent |
gptkb:ethinyl_estradiol_acetate
estradiol estrone |
| gptkbp:researchFocus |
thins cervical mucus
|
| gptkbp:route |
oral
transdermal |
| gptkbp:sideEffect |
headache
nausea breast tenderness mood changes |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:triggerType |
binds to estrogen receptors
|
| gptkbp:usedFor |
hormone replacement therapy
contraception |